The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.

The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.

The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.

To enhance expression of an antioxidant-related substance in an epidermis by using a diacylglycerol PEG adduct, a method for enhancing expression of an antioxidant-related substance in an epidermis is provided which includes applying a diacylglycerol PEG adduct to the epidermis as an active ingredient. The antioxidant-related substance is an oxidative stress response gene, an antioxidant enzyme, or an antioxidant protein. The diacylglycerol PEG adduct is selected from the group consisting of PEG-12 glycerol dimyristate (GDM12), PEG-12 glycerol distearate (GDS12), PEG-23 glycerol distearate (GDS23), PEG-23 glycerol dipalmitate (GDP23), and PEG-12 glycerol dioleate (GDO12).

To enhance expression of an antioxidant-related substance in an epidermis by using a diacylglycerol PEG adduct, a method for enhancing expression of an antioxidant-related substance in an epidermis is provided which includes applying a diacylglycerol PEG adduct to the epidermis as an active ingredient. The antioxidant-related substance is an oxidative stress response gene, an antioxidant enzyme, or an antioxidant protein. The diacylglycerol PEG adduct is selected from the group consisting of PEG-12 glycerol dimyristate (GDM12), PEG-12 glycerol distearate (GDS12), PEG-23 glycerol distearate (GDS23), PEG-23 glycerol dipalmitate (GDP23), and PEG-12 glycerol dioleate (GDO12).

Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.

Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.

Methoxy polyethylene glycol for use as a medicament, in particular in skin healing, wound healing and treatment of a microbial infection. A method for treating a medical device and/or implant to reduce or eliminate microbial contamination comprises applying a liquid formulation comprising methoxy polyethylene glycol. This invention relates to the novel discovery that methoxy polyethylene glycol, an inactive polymer with no known pharmacological effect, was able to come between microbes and a surface, removing the microbes or releasing the attachment or adherence of the microbes to the surface and thereby improving wound healing significantly, eliminating infections and colonies of microbes.

Methoxy polyethylene glycol for use as a medicament, in particular in skin healing, wound healing and treatment of a microbial infection. A method for treating a medical device and/or implant to reduce or eliminate microbial contamination comprises applying a liquid formulation comprising methoxy polyethylene glycol. This invention relates to the novel discovery that methoxy polyethylene glycol, an inactive polymer with no known pharmacological effect, was able to come between microbes and a surface, removing the microbes or releasing the attachment or adherence of the microbes to the surface and thereby improving wound healing significantly, eliminating infections and colonies of microbes.

Methoxy polyethylene glycol for use as a medicament, in particular in skin healing, wound healing and treatment of a microbial infection. A method for treating a medical device and/or implant to reduce or eliminate microbial contamination comprises applying a liquid formulation comprising methoxy polyethylene glycol. This invention relates to the novel discovery that methoxy polyethylene glycol, an inactive polymer with no known pharmacological effect, was able to come between microbes and a surface, removing the microbes or releasing the attachment or adherence of the microbes to the surface and thereby improving wound healing significantly, eliminating infections and colonies of microbes.